Pfizer Inc and Eli Lilly & Co
Jun 03, 2015
Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension
Drugs with better pharmacodymics and improved treatment algorithm with antiproliferative and anti-inflammatory treatments are needed! Pulmonary arterial hypertension (PAH) is rare lung disorder affecting pulmonary arteries. It is a fatal disease associated with the vasoconstriction and vascular remodeling that i...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
